Bottom line
Cardiovascular disease is the world's leading cause of death. The World Health Organization estimates that in 2022 it caused about 19.8 million deaths, roughly 32% of deaths worldwide, and that 85% of those were heart attacks and strokes. 11
The awkward feature is how quiet it is. One public account passes on a line often repeated among doctors: the most common way this disease "shows up" is a sudden heart attack that can kill. Often the first proof that the person had heart disease is that they just went down from it. 1 Even now, about a third of those first events are fatal. 1
The disease starts with a particle. Lipoproteins that carry apolipoprotein B (ApoB) — mostly low-density lipoprotein (LDL) — slip into the artery wall, get stuck, and light an inflammation that runs for decades and slowly becomes plaque. 23
Two sources both treat ApoB as the key cardiovascular-risk reading. 26 Other related pages take another line: risk factors for an early heart attack, small-vessel disease in the brain, and the omega-3 index. 8910 A coronary calcium score exists on imaging, but calcium shows up late. A score of zero is not a risk of zero. 3
It is not all bad news. The WHO writes that most cardiovascular disease can be prevented by acting on behavioral and environmental risks. 11
What it is
Cardiovascular disease is the umbrella for a large family of heart and blood-vessel diseases. The scene most people know is a heart attack: blood flow to part of the heart is limited, and muscle goes without oxygen. 8
The most common process behind it is atherosclerosis. One account puts it plainly. Plaque begins as a buildup, inside the artery wall, of particles that carry ApoB, most of them LDL. 5 Most heart attacks are plaque and clot together. Plaque ruptures or breaks, a clot forms, and the artery blocks acutely. That account writes that this combined process is called atherothrombosis. 5
Two ideas that get mixed up need to be split. LDL cholesterol (LDL-C) measures the mass of cholesterol inside the particles. ApoB marks the lipoprotein particles that carry it, mostly LDL. Two public accounts both list ApoB as a key marker of cardiovascular risk. 26
"Good cholesterol," HDL, is another idea spoiled by its label. For decades HDL-C wore that name, and it built a stubborn misunderstanding: a high HDL is some kind of free pass from cardiovascular disease. 4
Two supporting characters are easy to skip. One is a heart attack without atherosclerosis. The artery has no plaque, and the heart's blood supply still fails. Mechanisms such as spontaneous coronary artery dissection deserve particular attention in women. The other is small-vessel disease in the brain. About 5% of people over 50 are affected, nearly everyone over 90 has it, and an estimated quarter of strokes come from it. 59
Last is the omega-3 index: EPA plus DHA as a percentage of fatty acids in the red-cell membrane, treated as one reading of cardiovascular status. 10
Why it matters
The global ledger first: 19.8 million deaths, about 32%, with 85% concentrated in heart attacks and strokes. That is the WHO estimate for 2022. 11
Then the individual ledger. Epidemiology gathered in one account shows that people with diabetes have 4 to 5 times the risk of an early heart attack. Current smokers are above 4 times. People with disordered blood lipids are close to 3 times. 8
Time matters just as much. The CARDIA cohort followed more than 3,000 young adults. In young adulthood, 87% had lipid levels in an unfavorable range. More than twenty years later, people who had kept LDL lower had coronary calcium about 8% of the time. People whose LDL had been clearly high reached 44%. 12 Unfavorable lipids in youth line up with coronary calcium two decades on. That is an association in a cohort, not a destiny. 12
Silence makes it more dangerous. Waiting for chest pain often means intervening in the second half of the disease. 1 For women there is a further layer. Heart attacks without atherosclerosis are a reminder that no plaque does not mean no symptoms, and that symptoms are not something to wave off as anxiety. 5
The brain sits on the same net. Small-vessel disease becomes nearly universal with age. An estimate cited on the page: each 10 mmHg rise in blood pressure corresponds to about 65 days of older estimated brain age. 9
Different perspectives
Main positions
One position is steady. ApoB-carrying lipoproteins in the circulation, mostly LDL, drive atherosclerosis. That is not a hunch. It is a chain of evidence that includes dozens of large clinical trials, and Mendelian randomization studies line up closely with it. 2
That account is blunt about popular debunking essays. Skeptics grab one badly flawed study to challenge ApoB's causal role in atherosclerosis, and they will not put that study back into the whole literature. 2
On the coronary calcium score the stance is to use it, and not to worship it. Calcium is a scar response after plaque has been there a long time. It arrives late in the sequence. Inside the group with a calcium score of zero, risk is not even. People with the highest cumulative LDL exposure have about 3.4 times the event risk of the lowest group. 3
The same account takes apart "good cholesterol." Several drugs that push HDL-C very high failed, in large outcome trials, to deliver the cardiovascular benefit that had been promised. 4
A further warning: absence of atherosclerosis is not a reason to ignore chest pain, especially in women. There is specific writing on spontaneous coronary artery dissection and heart attacks that are not atherosclerotic. 5
An interview walked through the whole picture. The timeline has a section on the causal link between ApoB and atherosclerosis, and on monitoring ApoB. 7
Another entry point is risk markers plus things a person can actually do. A topic page says blood lipids — ApoB in particular — are a key marker of cardiovascular risk. 6
The action list on that same page is not exotic. Less sugar and saturated fat. More polyunsaturated fat and fiber. Regular exercise kept up. Statins used as prescribed. 6
The presentation is the notable part. Lifestyle moves and statins sit on one list, as tools on the same shelf, not as opposing camps. 6
That conversation is also the deepest cardiovascular episode on the platform, from cholesterol and ApoB through to how to monitor them. 7
A further entry is to make the mechanism clear. A heart-attack page starts from restricted blood flow and a heart muscle short of oxygen, and it puts the risk multiples for diabetes, smoking, and disordered lipids in plain view. 8
A small-vessel page moves the gaze from heart to brain. Prevalence climbs with age, and so does the blood-pressure link to brain age: about 65 days per 10 mmHg. 9
An omega-3 index page reads like a spec sheet for a marker. What it measures — EPA plus DHA as a share of the red-cell membrane — and why it is worth looking at. The page says it is associated with a 35% lower risk of premature death, and that it is a measurable biomarker of sudden cardiac death risk. 10
The marker comes from a paper by Harris and von Schacky. They proposed treating red-cell EPA plus DHA, the omega-3 index, as a new risk factor for death from coronary heart disease, and they wrote that an index of 8% or higher was tied to the strongest heart protection. 13
Where views agree and differ
Where the views line up: the particle burden that ApoB represents is the core reading of cardiovascular risk. Act early, with lifestyle first. A statin is a prescription tool. One topic page writes it on the same list as diet and exercise. 26
Where the weight differs, one account spends the most ink on risk strata and on the edges of the tools: how to read a calcium score of zero, how to read HDL. 34 Another turns the marker into a list of daily moves. 6 A further account adds two corners the others say less about: small vessels in the brain, and the omega-3 index. 910
Real disagreement is scarce, but two points are worth keeping. First, a calcium score of zero. A zero in a young adult is not a pass that skips further checks. Cumulative exposure is still at work. 3 Second, the standing of the omega-3 index. It is a risk factor in the research literature. It has not entered most routine lipid panels. 1013
PearHealth's synthesis
The part we take: treat ApoB as the lead of the lipid story and LDL-C as a supporting reading, looked at together. The time scale of prevention is decades, not the night before a checkup. 2612
The part we keep in view: strong causal evidence does not mean a personal outcome is fixed. Risk is set jointly by family history, blood pressure, blood sugar, smoking, and lipids. No single item gets to rule alone. 18
What we want to stress: this piece is a map, not a diagnostic document. Where a person actually stands depends on family history, baseline markers, and a clinician's risk stratification. 13
Two extremes are worth watching. Anxiety about a single marker, and the hope that one supplement solves everything. That 35% is an observational association at the population level, not a supplement prescription. The first move is still on that plain list. 610
How strong is the evidence
The hardest layer is the causal evidence on LDL and ApoB: dozens of large clinical trials, plus Mendelian randomization studies that agree closely. Those studies use genetic variants as a "natural randomization," which supplies a causal inference observational data cannot. 2
CARDIA is a long prospective cohort. More than 3,000 people were followed from young adulthood into middle age, linking lipids in youth with coronary calcium more than twenty years later. It is strong, and it is still an observational design. 12
The omega-3 index is more complicated. The 2004 paper that proposed it put a "new risk factor" hypothesis on the table. Population studies since then are mostly observational. 1013
The risk multiples — diabetes 4 to 5 times, smoking above 4 times, disordered lipids near 3 times — come from pooled epidemiology. They describe relative risk in groups. They do not convert directly into a personal probability. 8
The WHO figures on deaths and prevention are descriptive statistics. They answer how large, where, and why. They do not answer what a given person is to do. 11
Public commentaries are a layer of expert narrative. Their reading is useful, and each specific claim still has to land back on the studies or guidelines above before it counts.
What you can do
Directions many people take:
- Do not smoke, or put quitting on the schedule. Current smokers have more than 4 times the risk of an early heart attack compared with people who never smoked or who have quit. 8
- Point the diet the way one topic page lists it: less sugar, less saturated fat, more polyunsaturated fat, more fiber. 6
- Treat regular exercise as part of the week's plan, not as an optional reward. 6
- Measuring blood pressure is a small act that looks after both heart and brain. 9
- Build a personal lipid baseline that includes ApoB, then watch the trend rather than a single point. 26
- If a clinician has prescribed a statin, use it as prescribed, and talk with that clinician before changing it. 6
Questions worth raising with a clinician:
- Beyond a routine lipid panel, is an ApoB test worth adding? 26
- Lipoprotein(a) is mostly set by genes. Is one measurement in a lifetime worth doing?
- Given my family history, is a coronary calcium score reasonable now? 3
- I rarely eat fish. Is an omega-3 index worth measuring once? 10
- I have diabetes. On what schedule is cardiovascular risk worth rechecking? 8
Common misconceptions
Misconception one: no symptoms means no heart disease. In practice, the most common first sign of this disease is a sudden event, and a first event still kills about a third of the time. 1
Misconception two: a coronary calcium score of zero means all is well. Calcium appears late. Even among people with a score of zero, the ten-year event rate was 3.9% in the highest cumulative-LDL group and 1.3% in the lowest. The gap is easy to see. 3
Misconception three: a high HDL is a free pass. Decades of the "good cholesterol" label built that misunderstanding, and drugs that raise HDL-C did not deliver cardiovascular benefit in large trials. 4
Misconception four: cardiovascular disease is "a man's disease," and a woman's discomfort is anxiety. Heart attacks that are not atherosclerotic are seen especially in women. The symptoms deserve to be taken seriously, not waved off. 5
Misconception five: still young, so lipids can wait. In the CARDIA cohort, 87% of young adults had lipids in an unfavorable range, and coronary calcium more than twenty years later still lined up with those numbers. 12
How it connects to your blood work
A routine lipid panel, plus a few further tests, can sketch the outline of cardiovascular risk. On a report, they are worth reading together.
- Apolipoprotein B (apob): Two sources both treat it as the key reading of cardiovascular risk. 26
- LDL cholesterol (ldl-c): the number people watch most often. It measures cholesterol mass, not particle count. 2
- Non-HDL cholesterol (non-hdl-c): cholesterol-carrying particles other than HDL, packed into one look.
- Total cholesterol (total-cholesterol): a rough reading of the whole lipid picture.
- HDL cholesterol (hdl-c): it carries information. It is not a free pass. 4
- Triglycerides (triglycerides): a lipid tied to metabolic state, and one of the unfavorable young-adult lipids in CARDIA. 12
- Lipoprotein(a) (lp-a): mostly set by genes. One measurement shows that family line's hand.
- LDL particle concentration (ldl-p-nmr): a particle count by another method, a cross-check on ApoB.
- High-sensitivity C-reactive protein (hs-crp): a peripheral reading of chronic inflammation in the artery wall.
- HbA1c (hba1c): the line that links diabetes with heart-attack risk. 8
- Omega-3 index (omega-3-index): EPA plus DHA as a percentage of fatty acids in the red-cell membrane. 10
No single item predicts a cardiovascular future on its own. Their value is the trend and the combination, so a person and a clinician can rank the risks.